Women's HealthCare Market Growing at a CAGR of 13.2% - Exclusive Report by MarketsandMarkets™

2022-04-29 07:53:43 UTC | Healthcare & Pharmaceuticals
Women's HealthCare Market Growing at a CAGR of 13.2% - Exclusive Report by MarketsandMarkets™
The Women's HealthCare Market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period.

The Women's Health Care Market growth is largely driven by the growing incidence of chronic health conditions among women, government initiatives to curb population growth, growing demand for contraceptives to prevent unintended pregnancies, and the growing focus on R&D by key players for the development of advanced products. On the other hand, the reluctance to use contraceptives is a major factor limiting the Women's HealthCare Market growth. 

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136585329

Prolia is the largest and fastest-growing segment of the market.

Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. Prolia has shown a considerable year-on-year growth primarily due to increasing unit demand. Prolia has witnessed positive market growth owing to the increasing prevalence of postmenopausal osteoporosis in the US.

The postmenopausal osteoporosis segment is expected to grow at the highest CAGR during the forecast period.

On the basis of application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment is expected to grow at a higher CAGR during the forecast period. The growing prevalence of postmenopausal osteoporosis and a high risk of osteoporosis fractures are the prime factors that contribute towards the large share of this segment. Furthermore, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis also supports the growth of this segment. The postmenopausal osteoporosis segment also holds the largest share of the market owing to these factors.

Get 10% Customization on this Research Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136585329

In 2018, North America was the largest and the fastest-growing regional market for women's healthcare. The increasing median age of first-time pregnancies and the growing prevalence of PCOS and postmenopausal osteoporosis are the factors responsible for the growth of this regional segment. Furthermore, the growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending also support the growth of this market.

The prominent players in the global Women's Health Care Market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US).
Top